DRD2 and acute myeloid leukemia: Functional anti-leukemic effects were tested using 8 DRD2+ AML patient samples versus 5 DRD2lo/− controls (comprising 2 DRD2lo/− AML patients and 3 healthy donor samples; Figure 3C).